L1 Group’s funds under management tumbled in the March quarter as the performance of its flagship hedge fund was hit by the escalating war in the Middle East and investors kept pulling money from ...

CHICAGO, March 03, 2026 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, today ...

L1 Capital’s chief investment officers Raphael Lamm and Mark Landau couldn’t have asked for a better first year for their global long short fund. On the long side, the high-profile duo have ...

Paper defines the mechanism by which COUR Nanoparticles induce antigen-specific immune tolerance CHICAGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company ...

Gear-obsessed editors choose every product we review. We may earn commission if you buy from a link. Why Trust Us? Historically, I tend to gravitate toward upright vacuums. They have really powerful ...

Google Cloud is moving forward with plans to launch its own layer-1 (L1) blockchain, positioning the network as neutral infrastructure for global finance at a time when fintech competitors are ...

You will begin your studies with foundation courses in biology, chemistry, physics and mathematics. At the upper-division level, you will take a four-course sequence in advanced biological topics and ...

The human biology major will provide students with a broad biological understanding of our species, from molecules, genes, and cells to tissues, organ systems and organism/environment interactions.

Synovus Financial (SNV) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Synovus Financial Corp. (NYSE: SNV) and Pinnacle Financial Partners is fair to Synovus ...